Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

Background: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide have been shown to prolong survival in patients with advanced prostate cancer. However, there is limited evidence on the anticancer effect of a reduced dose of ARPIs. This study compared the prognosis in pa...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Shigetomo Yamada, Masaki Shiota, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Elsevier 2022-03-01
Ráidu:	Prostate International
Fáttát:	Abiraterone Androgen receptor pathway inhibitor Castration-resistant prostate cancer Dose reduction Enzalutamide
Liŋkkat:	http://www.sciencedirect.com/science/article/pii/S2287888221000556
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!